Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Analysis of Population Pharmacokinetic Data01:12

Analysis of Population Pharmacokinetic Data

416
Analysis of population pharmacokinetic data involves studying the behavior of drugs within diverse populations to understand their pharmacokinetic parameters. Traditional pharmacokinetic methods typically involve collecting samples from a few individuals and estimating these parameters. While these methods are commonly used, they have limitations in capturing the variability in drug response among individuals or heterogeneous populations. Population pharmacokinetics is employed to address these...
416
Factors Affecting Drug Response: Overview01:21

Factors Affecting Drug Response: Overview

2.5K
When it comes to infants and young children, they are typically administered smaller doses of medication in comparison to adults. This is primarily because their organ functions still need to fully develop, meaning their bodies are not as efficient at metabolizing or eliminating drugs. Additionally, their blood-brain barrier is more permeable than in adults. As a result, high concentrations of drugs can easily penetrate the central nervous system (CNS), potentially leading to neurological...
2.5K
Pharmacokinetic Models: Overview01:20

Pharmacokinetic Models: Overview

1.3K
Pharmacokinetic models utilize mathematical analysis to achieve a detailed quantitative understanding of a drug's life cycle within the body. They are instrumental in simulating a drug's pharmacokinetic parameters, predicting drug concentrations over time, optimizing dosage regimens, linking concentrations with pharmacologic activity, and estimating potential toxicity.
There are three primary types of models: empirical, compartment, and physiological. Empirical models, with minimal...
1.3K
Pharmacokinetic Models: Comparison and Selection Criterion01:26

Pharmacokinetic Models: Comparison and Selection Criterion

163
Physiological and compartmental models are valuable tools used in studying biological systems. These models rely on differential equations to maintain mass balance within the system, ensuring an accurate representation of the dynamic processes at play.
Physiological models take a detailed approach by considering specific molecular processes. They can predict drug distribution, metabolism, and elimination changes, providing a comprehensive understanding of how drugs interact with the body.
163
Model-Independent Approaches for Pharmacokinetic Data: Noncompartmental Analysis00:59

Model-Independent Approaches for Pharmacokinetic Data: Noncompartmental Analysis

137
Noncompartmental analyses offer an alternative method for describing drug pharmacokinetics without relying on a specific compartmental model. In this approach, the drug's pharmacokinetics are assumed to be linear, with the terminal phase log-linear. This assumption allows for simplified analysis and interpretation of the drug's behavior in the body.
One important characteristic of noncompartmental analyses is that drug exposure increases proportionally with increasing doses. This...
137
Nonlinear Pharmacokinetics: Overview01:19

Nonlinear Pharmacokinetics: Overview

616
Nonlinear or dose-dependent pharmacokinetics is a phenomenon that occurs when the pharmacokinetic parameters of certain drugs deviate from linear pharmacokinetics at higher doses. These drugs do not follow the expected first-order kinetics, where the rate of drug elimination is directly proportional to the drug concentration. Instead, they exhibit a nonlinear relationship, which can be attributed to several factors.
Nonlinearity can arise due to the saturation of plasma protein-binding or...
616

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Prevalence of Acute Kidney Injury and Its Association With Outcomes in Children With Severe Traumatic Brain Injury: A Secondary Exploratory Analysis of the 2014-2017 "Approaches and Decisions for Acute Pediatric Traumatic Brain Injury" Study.

Pediatric critical care medicine : a journal of the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies·2026
Same author

When Science Outpaces Infrastructure: People, Process, and Technology Challenges for Precision Dosing in Children.

Clinical and translational science·2026
Same author

Bayesian dosage adjustment of tacrolimus in kidney transplantation: a systematic review.

Postgraduate medicine·2026
Same author

Extracorporeal membrane oxygenation, acute kidney injury, fluid balance, and continuous renal replacement therapy: Acute Disease Quality Initiative (ADQI) and Extracorporeal Life Support Organization (ELSO) joint consensus conference.

Intensive care medicine·2026
Same author

Ultrasound-enabled refreshable electrochemical sensors for cardiac biomarker monitoring.

Biosensors & bioelectronics·2026
Same author

Small patients, big gaps: why adult CRRT timing evidence does not translate to children.

Critical care (London, England)·2026

Related Experiment Video

Updated: Sep 30, 2025

A Controlled Mouse Model for Neonatal Polymicrobial Sepsis
14:54

A Controlled Mouse Model for Neonatal Polymicrobial Sepsis

Published on: January 27, 2019

11.3K

Optimizing Vancomycin Dosing and Monitoring in Neonates and Infants Using Population Pharmacokinetic Modeling.

Praneeth Jarugula1, Ayse Akcan-Arikan2,3, Flor Munoz-Rivas2

  • 1Center for Translational Medicine, Department of Pharmacy Practice and Sciences, University of Maryland School of Pharmacy, Baltimore, Maryland, USA.

Antimicrobial Agents and Chemotherapy
|March 16, 2022
PubMed
Summary

Optimal vancomycin dosing for infants under 180 days was determined using population pharmacokinetic modeling. Dosing strategies were stratified by serum creatinine and postmenstrual age to achieve target vancomycin exposure.

Keywords:
PK modelingneonatespediatricspharmacokineticsvancomycin

More Related Videos

Probiotic Studies in Neonatal Mice Using Gavage
10:36

Probiotic Studies in Neonatal Mice Using Gavage

Published on: January 27, 2019

19.9K
A Neonatal Imaging Model of Gram-Negative Bacterial Sepsis
08:46

A Neonatal Imaging Model of Gram-Negative Bacterial Sepsis

Published on: August 12, 2020

6.5K

Related Experiment Videos

Last Updated: Sep 30, 2025

A Controlled Mouse Model for Neonatal Polymicrobial Sepsis
14:54

A Controlled Mouse Model for Neonatal Polymicrobial Sepsis

Published on: January 27, 2019

11.3K
Probiotic Studies in Neonatal Mice Using Gavage
10:36

Probiotic Studies in Neonatal Mice Using Gavage

Published on: January 27, 2019

19.9K
A Neonatal Imaging Model of Gram-Negative Bacterial Sepsis
08:46

A Neonatal Imaging Model of Gram-Negative Bacterial Sepsis

Published on: August 12, 2020

6.5K

Area of Science:

  • Pharmacokinetics and Pharmacodynamics
  • Pediatric Pharmacology
  • Infectious Disease Therapeutics

Background:

  • Vancomycin is crucial for treating serious infections in infants.
  • Optimizing vancomycin dosing in neonates and infants is challenging due to immature organ function.
  • Achieving therapeutic vancomycin exposure (AUC24) is critical for efficacy and minimizing resistance.

Purpose of the Study:

  • To determine optimal vancomycin starting dose regimens in infants ≤180 days old.
  • To achieve the highest probability of target attainment for area under the concentration-time curve (AUC24) of ≥400.
  • To evaluate the relationship between serum creatinine and vancomycin clearance in neonates.

Main Methods:

  • Retrospective population pharmacokinetic (PK) study of 934 pediatric patients ≤180 days old.
  • Developed a one-compartment PK model using Pumas (v1.0.5).
  • Simulated various dosing regimens to assess target attainment probabilities and analyzed covariate effects (WT, SCR, PMA).

Main Results:

  • Body weight (WT), serum creatinine (SCR), and postmenstrual age (PMA) were significant covariates on vancomycin clearance.
  • No clear relationship between vancomycin clearance and SCR was observed in infants <10 days postnatal age (PNA).
  • Dosing regimens were stratified by SCR (≥10 days PNA) and PMA (<10 days PNA) to optimize vancomycin exposure.

Conclusions:

  • A vancomycin population PK model was developed for pediatric patients <180 days old.
  • The model incorporates WT, SCR, and PMA to guide dosing.
  • Stratified dosing recommendations improve the probability of achieving therapeutic vancomycin targets in this vulnerable population.